News

16.12.20 Medannex chosen by Welp Magazine as a company to watch in the UK Clinical Trials space
17.08.20 Medannex completes final tranche of £11m Series B investment, led by Morningside Venture Capital
22.06.20 Medannex presents data on its immunomodulatory anticancer agent MDX-124 at AACR Annual Meeting
15.06.20 Medannex announces Innovate UK grant award for novel cancer therapeutic development
10.03.20 Medannex announces new immunomodulatory approach to cancer treatment at Nature conference
16.02.20 Medannex shortlisted in two categories at Scotland’s Life Sciences Awards
  2. 1
  3. 2
  4. 3
  5. 4